Liver drug study halted before it began: no patients enrolled
NCT ID NCT04244877
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This study aimed to see if the antibiotic rifaximin could help people with liver cirrhosis who have a hidden form of brain fog (covert hepatic encephalopathy) and an overgrowth of bacteria in the small intestine. Researchers planned to give 40 patients rifaximin for 8 weeks and test their thinking skills and gut function. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS, LIVER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.